Iconovo announced that it has signed a letter of intent with CDMO Lonza related to development of spray dried formulation of inhaled biologics. The companies announced in January 2025 that Lonza would develop spray dried dry powder formulations of a biologic for delivery by Iconovo’s ICOone nasal device. According to Iconovo, the extension of the deal reflects an intent for “a more strategic long-term collaboration, solidifying their respective stakes in the field of biologics.”
In 2024, Iconovo announced that it would develop inhaled GLP-1 receptor agonists for the treatment of obesity. The company recently said that it had initiated a feasibility study of a compound delivered by its ICOone Nasal device for “a large multinational company.”
Iconovo interim CEO Anders Månsson commented, “The parties have so far reached the signing of a letter of intent. The next step is to inventory a list of potential projects for collaboration and more specifically agree on the terms of a possibly extended collaboration in this strategic area.”
Lonza VP, Commercial Development, Advanced Synthesis, Jan Vertommen said, “We also consider inhalable biologics to be an area of great interest, and we look forward to exploring the possibilities of extending our collaboration with Iconovo.”
Read the Iconovo press release
